VolitionRx (VNRX) Q2 FY26 earnings call

VolitionRx reported mixed Q2 FY26 results with flat quarterly revenue but strong first-half growth, driven by significant progress across its diagnostic product pillars. The company highlighted advancements in its Nu.Q NETs lateral flow assay for sepsis, the Capture-Seq technology for cancer detection, and a highly accurate feline cancer test, all aimed at expanding addressable markets and securing licensing agreements. Management continues to focus on cost reduction and advancing clinical and commercial milestones.